Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett King

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
International Journal of Dermatology|October 10, 2025
Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3Ernest H Law, Bintu Sherif, Arash Mostaghimi, et al.
The Journal of Allergy and Clinical Immunology|November 1, 2020
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseasesWilliam Damsky, Danielle Peterson, Julie Ramseier, et al.
Dermatology and Therapy|November 22, 2023
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia AreataMaryanne M Senna, Ohsang Kwon, Bianca M Piraccini, et al.
BMC Oral Health|June 13, 2026
Deep learning models for the detection of dental-findings and tooth-types using video dataJulia Michelin, Ayesha Nooruddin, Aamna Khalid, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Dermatology and Therapy|July 20, 2022
A Qualitative Study to Develop and Evaluate the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) MeasuresHelen Kitchen, Kavita Gandhi, Chloe Carmichael, et al.
The British Journal of Dermatology|April 3, 2025
Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with BaricitinibArash Mostaghimi, Brittany Craiglow, Brett King, et al.
Nature Reviews. Disease Primers|November 6, 2025
Alopecia areataBenjamin Ungar, Yael Renert-Yuval, Ncoza C Dlova, et al.
Journal of the American Academy of Dermatology|November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Advances in Therapy|July 22, 2021
Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance ClaimsMaryanne Senna, Justin Ko, Antonella Tosti, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
International Journal of Dermatology|October 10, 2025
Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3Ernest H Law, Bintu Sherif, Arash Mostaghimi, et al.
The Journal of Allergy and Clinical Immunology|November 1, 2020
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseasesWilliam Damsky, Danielle Peterson, Julie Ramseier, et al.
Dermatology and Therapy|November 22, 2023
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia AreataMaryanne M Senna, Ohsang Kwon, Bianca M Piraccini, et al.
BMC Oral Health|June 13, 2026
Deep learning models for the detection of dental-findings and tooth-types using video dataJulia Michelin, Ayesha Nooruddin, Aamna Khalid, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Dermatology and Therapy|July 20, 2022
A Qualitative Study to Develop and Evaluate the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) MeasuresHelen Kitchen, Kavita Gandhi, Chloe Carmichael, et al.
The British Journal of Dermatology|April 3, 2025
Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with BaricitinibArash Mostaghimi, Brittany Craiglow, Brett King, et al.
Nature Reviews. Disease Primers|November 6, 2025
Alopecia areataBenjamin Ungar, Yael Renert-Yuval, Ncoza C Dlova, et al.
Journal of the American Academy of Dermatology|November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Advances in Therapy|July 22, 2021
Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance ClaimsMaryanne Senna, Justin Ko, Antonella Tosti, et al.
Pageof 8